Shopping Cart 0
Cart Subtotal
USD 0

COVID-19 Impact on Global Preeclampsia Diagnostics Market by Test Type(Blood Test and Urine Analysis); By Product Type (Instruments and Consumables); By End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others.) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option : NO
Copy Option : No
Download Option: No
Deliverable Format : Excel viewable on the website via username

Excel Only
USD 2800

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3850

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 7500

Details

Product Overview

Elevated blood pressure and elevated protein in the urine of pregnant women are characterized by preeclampsia, a rapidly progressive condition. It is one of the hypertensive pregnancy disorders that is responsible for accelerating the rate of maternal & prenatal morbidity and mortality in developing and emerging countries. It may lead to preterm birth and other complications, such as seizures or eclampsia, organ failure, and death if not diagnosed at an early stage. For instance, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 child fatalities worldwide per year, according to the Preeclampsia Foundation.

Market Highlights

Global Preeclampsia Diagnostics Market size was registered at USD 1.07 billion in 2019 and is estimated to reach USD 3.64 billion by 2030, registering a CAGR of 11.92% from 2020 to 2030. Global market growth in preeclampsia diagnostics is driven mainly by increasing preeclampsia incidences globally. The growth of the market for preeclampsia diagnostics is expected to be driven by the rapidly increasing demand for its diagnosis and care. The rise in maternal & perinatal mortality and morbidity rates is also expected to increase demand among pregnant women for early diagnosis of preeclampsia. Furthermore, growing awareness among healthcare professionals of the successful screening methods for the condition and increasing knowledge of the signs and symptoms associated with preeclampsia among pregnant mothers and are likely to fuel rapid growth in the demand for preeclampsia diagnostics over the forecast period.

                                        Global Preeclampsia Diagnostics Market Opportunity Analysis                                                                               

Source: Fatpos Global

Global Preeclampsia Diagnostics Market: Segments

Preeclampsia Diagnostics Market is segmented based on test type, product type, end-user, and region.

By Test Type (in %), Preeclampsia Diagnostics Market, 2019

The blood test segment is anticipated to register XX% of the market share during the forecasted period.

By test type, the market can be segmented into blood test and urine analysis. The blood test segment held the largest market share in preeclampsia diagnostics and is expected to grow at a significantly high CAGR over the forecast period. This is due to the benefits provided by blood tests in the efficient identification of the biomarkers responsible for preeclampsia. Many organizations are embracing the use of blood tests to diagnose preeclampsia, which shortly may further boost the market for further blood screening tests for the same.

By Product Type (in %), Preeclampsia Diagnostics Market, 2019

The consumables segment accounted for XX% of the nation’s volume in 2019

The product type segment can be classified into instruments and consumables. The consumables category held the largest market share. It is anticipated that the growing launch of many reagents & kits by different players for the rapid detection of biomarkers suggesting preeclampsia in the coming years would increase demand for consumables.

By End User (in %), Preeclampsia Diagnostics Market, 2019

The diagnostics center segment is anticipated to register XX% of the market share during the forecasted period.

By end-user, the market can be segmented into hospitals, specialty clinics, diagnostic centers, and others. The diagnostic Centre category captured substantial market revenue for preeclampsia diagnostics. This is largely due to the existence of specialized diagnostic equipment at these centers. They in the earlier stage include correct diagnosis of preeclampsia.

                                      

Source: Fatpos Global

Global Preeclampsia Diagnostics Market Dynamics:

Increasing research and development and government funding to increase the market growth

Global market growth in preeclampsia diagnostics is driven mainly by increasing preeclampsia incidences globally. The growth of the market for preeclampsia diagnostics is expected to be driven by the rapidly increasing demand for its diagnosis and care. The rise in maternal & perinatal mortality and morbidity rates is also expected to increase demand among pregnant women for early diagnosis of preeclampsia. Rising R&D to groundbreaking new tests for detecting biomarkers suggesting preeclampsia is also expected to fuel market growth over the forecast period. Furthermore, growing awareness among healthcare professionals of the successful screening methods for the condition and increasing knowledge of the signs and symptoms associated with preeclampsia among pregnant mothers and are likely to fuel rapid growth in the demand for preeclampsia diagnostics over the forecast period.

Lack of knowledge to hinder the market growth

A single elevated rise in blood pressure in pregnant women does not accurately diagnose preeclampsia. Given the rising incidence of preeclampsia, many pregnant women across the globe lack awareness of the word preeclampsia and its associated complications. Also, when signs such as high blood pressure have already manifested, women who experience preeclampsia are not aware of this life-threatening condition until late in their pregnancy. Thus, given the high prevalence of the disease, limited knowledge of the disease limits the growth of the industry.

Global Preeclampsia Diagnostics Market: Regions

In terms of value and volume, North America accounted for XX% of total market volume share in 2019

North America is projected to account for the high market share on the global preeclampsia diagnostics market due to advances in diagnostic testing and the increased prevalence of pregnancy-related diseases in the country. Europe also accounted for a substantial market share due to an increase in the region's incidence of preeclampsia. The governments of European countries are focusing on launching awareness campaigns for the prevention and diagnosis and care of women suffering from preeclampsia. During the forecast era, the rise in disease prevalence is expected to fuel the growth of the preeclampsia diagnostic market. During the forecast period, the demand in APAC is expected to register a high CAGR. During the forecast period, an increase in demand for new and advanced diagnostic tools, an increase in R&D programs, and government involvement in disease awareness are expected to fuel market growth in the region.

The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.

                                            

Source: Fatpos Global

Global Preeclampsia Diagnostics Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – the United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Preeclampsia Diagnostics Market: Impact of COVID-19

Global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. The pandemic of coronavirus has resulted in an unprecedented demand for our health system. The rise of COVID-19 cases has raised global concerns for older people, children, and pregnant women. During these days, a substantial rise in preeclampsia testing was observed due to the number of pregnancies during the lockout, postponed or canceled abortion cases due to the lack of access to midwives or health care facilities, and high risks associated with the occurrence of preeclampsia among pregnant women positive for COVID-19. The lockdown would lead to 7 million premature pregnancies globally, according to a report by UNICEF. Also, due to the prevalence of proteinuria present in both conditions, there is an increased diagnostic problem associated with current COVID-19 cases and preeclampsia. Also, positive government support in the form of guideline amendments to deal with prenatal cases and preeclampsia management and maintaining the availability of health care facilities amid loading on them would boost demand for preeclampsia screening in 2020.

Preeclampsia Diagnostics Market: Competitive landscape

New technological advancements in the Preeclampsia Diagnostics Market, as well as large production output of the product by key players, are likely to increase the market growth. In this segment, the pharmaceutical companies have dramatically strengthened their supply chain management, enhanced their R&D capabilities, and invested more in their production management and quality control.

Global Preeclampsia Diagnostics Market: Key players

  • Bayer AG
    • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
  • Roche
  • PerkinElmer
  • DRG INSTRUMENTS GMBH
  • Thermo Fisher Scientific
  • Diabetomics, Inc.
  • Metabolomic Diagnostics Ltd.
  • Sera Prognostics
  • Siemens Healthineers 
  • Other prominent players

Preeclampsia Diagnostics Market segments: -

  • By Test Type:
    • Blood test
    • Urine analysis
  • By Product Type:
    • Instruments
    • Consumables
  • By End User:
    • Hospitals
    • Specialty clinics
    • Diagnostic centers
  • Others
  • Preeclampsia Diagnostics Market dynamics
  • Preeclampsia Diagnostics Market size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints
READ MORE

Table Of Content

Scope

Contents        

  1. Executive Summary
  2. Preeclampsia Diagnostics Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  6. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  7. Recent Development, Policies & Regulatory Landscape
  8. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  9. Preeclampsia Diagnostics Market Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  10. Preeclampsia Diagnostics Market
    1. Market Size & forecast, 2019A-2030F
      1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11. Preeclampsia Diagnostics Market: Market Segmentation
    1.       By Regions
      1. North America:(U.S. and Canada)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12. Preeclampsia Diagnostics Market: Market Segmentation
    1. By test type: Market Share (2020-2030F)
      1. Blood test, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Urine analysis, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    2. By product type: Market Share (2020-2030F)
      1. instruments, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. consumables, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    3. By end-user: Market Share (2020-2030F)
      1. hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. specialty clinics, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. diagnostic centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  13. Company Profile
    1. Bayer AG
      1. Company Overview
      2. Company Total Revenue (Financials)
      3.  Market Potential
      4. Global Presence
      5. Key Performance Indicators
      6. SWOT Analysis
      7.  Product Launch
    2. Roche
    3. PerkinElmer
    4. DRG INSTRUMENTS GMBH
    5. Thermo Fisher Scientific
    6. Diabetomics, Inc.
    7. Metabolomic Diagnostics Ltd.
    8. Sera Prognostics
    9. Siemens Healthineers
    10. Other prominent players
  14. Consultant Recommendation

**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Licence Rights

  • Single User License:

    Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization. The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete/part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

  •  
  • Hard Copy License:

    The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

  •  
  • Corporate User License:

    Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Product Overview

Elevated blood pressure and elevated protein in the urine of pregnant women are characterized by preeclampsia, a rapidly progressive condition. It is one of the hypertensive pregnancy disorders that is responsible for accelerating the rate of maternal & prenatal morbidity and mortality in developing and emerging countries. It may lead to preterm birth and other complications, such as seizures or eclampsia, organ failure, and death if not diagnosed at an early stage. For instance, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 child fatalities worldwide per year, according to the Preeclampsia Foundation.

Market Highlights

Global Preeclampsia Diagnostics Market size was registered at USD 1.07 billion in 2019 and is estimated to reach USD 3.64 billion by 2030, registering a CAGR of 11.92% from 2020 to 2030. Global market growth in preeclampsia diagnostics is driven mainly by increasing preeclampsia incidences globally. The growth of the market for preeclampsia diagnostics is expected to be driven by the rapidly increasing demand for its diagnosis and care. The rise in maternal & perinatal mortality and morbidity rates is also expected to increase demand among pregnant women for early diagnosis of preeclampsia. Furthermore, growing awareness among healthcare professionals of the successful screening methods for the condition and increasing knowledge of the signs and symptoms associated with preeclampsia among pregnant mothers and are likely to fuel rapid growth in the demand for preeclampsia diagnostics over the forecast period.

                                        Global Preeclampsia Diagnostics Market Opportunity Analysis                                                                               

Source: Fatpos Global

Global Preeclampsia Diagnostics Market: Segments

Preeclampsia Diagnostics Market is segmented based on test type, product type, end-user, and region.

By Test Type (in %), Preeclampsia Diagnostics Market, 2019

The blood test segment is anticipated to register XX% of the market share during the forecasted period.

By test type, the market can be segmented into blood test and urine analysis. The blood test segment held the largest market share in preeclampsia diagnostics and is expected to grow at a significantly high CAGR over the forecast period. This is due to the benefits provided by blood tests in the efficient identification of the biomarkers responsible for preeclampsia. Many organizations are embracing the use of blood tests to diagnose preeclampsia, which shortly may further boost the market for further blood screening tests for the same.

By Product Type (in %), Preeclampsia Diagnostics Market, 2019

The consumables segment accounted for XX% of the nation’s volume in 2019

The product type segment can be classified into instruments and consumables. The consumables category held the largest market share. It is anticipated that the growing launch of many reagents & kits by different players for the rapid detection of biomarkers suggesting preeclampsia in the coming years would increase demand for consumables.

By End User (in %), Preeclampsia Diagnostics Market, 2019

The diagnostics center segment is anticipated to register XX% of the market share during the forecasted period.

By end-user, the market can be segmented into hospitals, specialty clinics, diagnostic centers, and others. The diagnostic Centre category captured substantial market revenue for preeclampsia diagnostics. This is largely due to the existence of specialized diagnostic equipment at these centers. They in the earlier stage include correct diagnosis of preeclampsia.

                                      

Source: Fatpos Global

Global Preeclampsia Diagnostics Market Dynamics:

Increasing research and development and government funding to increase the market growth

Global market growth in preeclampsia diagnostics is driven mainly by increasing preeclampsia incidences globally. The growth of the market for preeclampsia diagnostics is expected to be driven by the rapidly increasing demand for its diagnosis and care. The rise in maternal & perinatal mortality and morbidity rates is also expected to increase demand among pregnant women for early diagnosis of preeclampsia. Rising R&D to groundbreaking new tests for detecting biomarkers suggesting preeclampsia is also expected to fuel market growth over the forecast period. Furthermore, growing awareness among healthcare professionals of the successful screening methods for the condition and increasing knowledge of the signs and symptoms associated with preeclampsia among pregnant mothers and are likely to fuel rapid growth in the demand for preeclampsia diagnostics over the forecast period.

Lack of knowledge to hinder the market growth

A single elevated rise in blood pressure in pregnant women does not accurately diagnose preeclampsia. Given the rising incidence of preeclampsia, many pregnant women across the globe lack awareness of the word preeclampsia and its associated complications. Also, when signs such as high blood pressure have already manifested, women who experience preeclampsia are not aware of this life-threatening condition until late in their pregnancy. Thus, given the high prevalence of the disease, limited knowledge of the disease limits the growth of the industry.

Global Preeclampsia Diagnostics Market: Regions

In terms of value and volume, North America accounted for XX% of total market volume share in 2019

North America is projected to account for the high market share on the global preeclampsia diagnostics market due to advances in diagnostic testing and the increased prevalence of pregnancy-related diseases in the country. Europe also accounted for a substantial market share due to an increase in the region's incidence of preeclampsia. The governments of European countries are focusing on launching awareness campaigns for the prevention and diagnosis and care of women suffering from preeclampsia. During the forecast era, the rise in disease prevalence is expected to fuel the growth of the preeclampsia diagnostic market. During the forecast period, the demand in APAC is expected to register a high CAGR. During the forecast period, an increase in demand for new and advanced diagnostic tools, an increase in R&D programs, and government involvement in disease awareness are expected to fuel market growth in the region.

The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.

                                            

Source: Fatpos Global

Global Preeclampsia Diagnostics Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – the United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Preeclampsia Diagnostics Market: Impact of COVID-19

Global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. The pandemic of coronavirus has resulted in an unprecedented demand for our health system. The rise of COVID-19 cases has raised global concerns for older people, children, and pregnant women. During these days, a substantial rise in preeclampsia testing was observed due to the number of pregnancies during the lockout, postponed or canceled abortion cases due to the lack of access to midwives or health care facilities, and high risks associated with the occurrence of preeclampsia among pregnant women positive for COVID-19. The lockdown would lead to 7 million premature pregnancies globally, according to a report by UNICEF. Also, due to the prevalence of proteinuria present in both conditions, there is an increased diagnostic problem associated with current COVID-19 cases and preeclampsia. Also, positive government support in the form of guideline amendments to deal with prenatal cases and preeclampsia management and maintaining the availability of health care facilities amid loading on them would boost demand for preeclampsia screening in 2020.

Preeclampsia Diagnostics Market: Competitive landscape

New technological advancements in the Preeclampsia Diagnostics Market, as well as large production output of the product by key players, are likely to increase the market growth. In this segment, the pharmaceutical companies have dramatically strengthened their supply chain management, enhanced their R&D capabilities, and invested more in their production management and quality control.

Global Preeclampsia Diagnostics Market: Key players

  • Bayer AG
    • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
  • Roche
  • PerkinElmer
  • DRG INSTRUMENTS GMBH
  • Thermo Fisher Scientific
  • Diabetomics, Inc.
  • Metabolomic Diagnostics Ltd.
  • Sera Prognostics
  • Siemens Healthineers 
  • Other prominent players

Preeclampsia Diagnostics Market segments: -

  • By Test Type:
    • Blood test
    • Urine analysis
  • By Product Type:
    • Instruments
    • Consumables
  • By End User:
    • Hospitals
    • Specialty clinics
    • Diagnostic centers
  • Others
  • Preeclampsia Diagnostics Market dynamics
  • Preeclampsia Diagnostics Market size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints
READ MORE

Scope

Contents        

  1. Executive Summary
  2. Preeclampsia Diagnostics Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  6. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  7. Recent Development, Policies & Regulatory Landscape
  8. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  9. Preeclampsia Diagnostics Market Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  10. Preeclampsia Diagnostics Market
    1. Market Size & forecast, 2019A-2030F
      1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11. Preeclampsia Diagnostics Market: Market Segmentation
    1.       By Regions
      1. North America:(U.S. and Canada)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12. Preeclampsia Diagnostics Market: Market Segmentation
    1. By test type: Market Share (2020-2030F)
      1. Blood test, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Urine analysis, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    2. By product type: Market Share (2020-2030F)
      1. instruments, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. consumables, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    3. By end-user: Market Share (2020-2030F)
      1. hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. specialty clinics, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. diagnostic centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  13. Company Profile
    1. Bayer AG
      1. Company Overview
      2. Company Total Revenue (Financials)
      3.  Market Potential
      4. Global Presence
      5. Key Performance Indicators
      6. SWOT Analysis
      7.  Product Launch
    2. Roche
    3. PerkinElmer
    4. DRG INSTRUMENTS GMBH
    5. Thermo Fisher Scientific
    6. Diabetomics, Inc.
    7. Metabolomic Diagnostics Ltd.
    8. Sera Prognostics
    9. Siemens Healthineers
    10. Other prominent players
  14. Consultant Recommendation

**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

  • Single User License:

    Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization. The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete/part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

  •  
  • Hard Copy License:

    The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

  •  
  • Corporate User License:

    Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS